ALT 8-K 2026-11-12

Altimmune, Inc. (ALT) 8-K dated 2026-11-12 — accession 0001326190-26-000067.

Altimmune, Inc. (ALT) is a biotechnology company listed on US.

ALT: Altimmune Announces Third Quarter 2026 Financial Results and Business U…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported ALT revenue for 2025-12-31 was $41.0K. Net income was -$88.1M. Revenue was up 105.0% from 2024-12-31 to 2025-12-31. ALT currently screens at market cap $527.0M.

Not investment advice. The ALT SEC hub lists recent forms. The stock page is the research view.